GlassScriptPhysician profile
Steven C Manley
NPI 1699112953
$5,554.03
in general payments reported to CMS, 2019-2025
41 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,252 · 2022: $1,079 · 2023: $1,094 · 2024: $1,062 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,220 · Education: $2.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.48 |
| Education | $2.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $739.75 | 2021-2024 | Aveed, Xiaflex |
| Astellas Pharma US INC | $551.83 | 2021-2025 | Xtandi, Myrbetriq, Veozah |
| Pfizer INC. | $368.74 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $343.89 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $330.42 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $322.46 | 2023-2025 | Orgovyx |
| Blue Earth Diagnostics | $302.01 | 2021-2023 | |
| Tolmar, INC. | $301.04 | 2023-2025 | Jatenzo, Eligard |
| Astrazeneca Pharmaceuticals LP | $300.27 | 2021-2025 | Lynparza |
| Axonics, INC. | $230.78 | 2021-2024 | Bulkamid |
| Ferring Pharmaceuticals INC. | $200.67 | 2024-2025 | Adstiladrin |
| Myovant Sciences INC. | $183.94 | 2021-2022 | |
| Antares Pharma, INC. | $164.31 | 2021-2025 | Xyosted |
| Medtronic, INC. | $105.89 | 2021-2025 | Interstim |
| Dendreon Pharmaceuticals LLC | $105.37 | 2021-2024 | Provenge |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Manley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.